Similarly, in graft-versus-host disease, tamibarotene alleviated tissue inflammation and fibrosis exclusively in the skin by inhibiting the release of cytokines from TH1 and TH17 cells and by decreasing the expression of TGF-β [9]. The gene discussed is TGFB1; the disease is graft versus host disease.